SHAREHOLDER ALERT: WeissLaw LLP Reminds PROS, IPHI and OBLN Shareholders About Its Ongoing Investigations

NEW YORK, March 8, 2021 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]

ProSight Global, Inc. (NYSE: PROS)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ProSight Global, Inc. (NYSE: PROS) in connection with the proposed acquisition of the company by TowerBrook Capital Partners L.P. ("TowerBrook") and Further Global Capital Management ("Further Global"). Under the terms of the merger agreement, affiliates of TowerBrook and Further Global will acquire all outstanding shares of common stock of PROS for $12.85 per share in cash. If you own PROS shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/pros/

Inphi Corporation (NASDAQ: IPHI)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Inphi Corporation (NASDAQ: IPHI) in connection with the company's proposed merger with Marvell Technology Group Ltd. Under the terms of the agreement, IPHI shareholders will receive $66.00 in cash and 2.323 shares of the newly-combined company for each IPHI share that they own. If you own IPHI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/iphi/

Obalon Therapeutics, Inc. (NASDAQ: OBLN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. (NASDAQ: OBLN) in connection with the proposed merger of the company with ReShape Lifesciences Inc. ("ReShape"). Under the terms of the merger agreement, ReShape will acquire OBLN in an all-stock transaction, pursuant to which OBLN will be renamed ReShape Lifesciences Inc. If you own OBLN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/obln/

SOURCE WeissLaw LLP

Related Links

http://weisslawllp.com